Clinical trial Recruiting at 1 site Interventional Ages 18 and up

Stimulation of nerves to treat obstructive sleep apnea

Official title: Ansa Cervicalis and Hypoglossal Nerve Stimulation in Obstructive Sleep Apnea

Run by Vanderbilt University Medical Center · NCT05501236 · Data updated 2026-11-12

This study is testing if stimulating certain nerves can help people with obstructive sleep apnea breathe better during sleep, especially for those who haven't found relief with other treatments.

More Obstructive Sleep Apnea trials

Quick facts

Study typeInterventional
Ages18 Years and up
SexAll
Enrollment100 (estimated)
SponsorVanderbilt University Medical Center
Academic / other
Locations1 site (Nashville, Tennessee)
StatusRecruiting
StartedNovember 3, 2022
Main results expectedMay 30, 2027
Study endsNovember 30, 2027
Registry record updatedJune 29, 2026
Trial IDNCT05501236 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Ideal candidates include adults with a BMI between 25 and 40 kg/m2 and an apnea-hypopnea index (AHI) of 20 to 80 events per hour.

Probably not a fit

Patients with chronic use of opiate medications, other sleep disorders, or significant comorbidities may not benefit from this study.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study investigates the effects of ansa cervicalis stimulation (ACS) alone and in combination with hypoglossal nerve stimulation (HNS) on patients with obstructive sleep apnea (OSA). It aims to explore how these stimulation techniques can improve airway patency during sleep by targeting specific muscles involved in maintaining upper airway structure. The study will utilize polysomnography (PSG) and drug-induced sleep endoscopy (DISE) to assess the physiological responses and effectiveness of the interventions. The goal is to provide a new therapeutic option for patients who do not respond adequately to existing treatments like positive airway pressure (PAP).

Why it matters

Potential benefit: If successful, this approach could offer a new treatment option for patients with obstructive sleep apnea who struggle with current therapies.

How similar studies have gone: While hypoglossal nerve stimulation has shown promise, the specific combination of ACS and HNS is a novel approach that has not been extensively tested in prior studies.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

1. Consenting adults with BMI≥ 25 and ≤ 40 kg/m2
2. Obstructive sleep apnea with an AHI between 20 and 80 events/hr (with hypopneas defined by 4% oxyhemoglobin desaturations); ≥80% obstructive events.

Exclusion Criteria:

1. Chronic use of opiate medications, illicit drug use, or alcohol dependency
2. Other known concomitant sleep disorder (e.g., central sleep apnea, periodic limb movements, narcolepsy)
3. Clinical history or evidence of cardiopulmonary disease (or oxygen use), liver, renal, immunodeficiency, neurodegenerative diseases, or previous adverse reactions to anesthesia.
4. Prior upper airway reconstructive surgery excluding tonsillectomy (e.g., cleft palate repair, uvulopalatopharyngoplasty)
5. Indwelling neurostimulation device (e.g. cardiac pacemaker, spinal, vagal, or hypoglossal nerve stimulator)

Where it's running

  • Vanderbilt University Medical Center
    Nashville, Tennessee, United States
    Recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.